Commercial Planning for AT-GAA
Student: Peter Misko, 2020-2021
Sponsor: Amicus Therapeutics, Cranbury Township, NJ, USA
My project involves the commercial planning for the new drug, AT-GAA, currently in development by Amicus Therapeutics for the treatment of Pompe Disease. This drug is currently in a Phase III Clinical Trial and is projected to go to market by the end of 2021-early 2022. Patients with Pompe Disease lack the enzyme Acid alpha-glucosidase (GAA) that is needed to break down glycogen, resulting in improper muscle function, eventually leading to muscular and respiratory failure. This new drug will play the role normally functioning GAA has by reducing the levels of glycogen within the body. My role in this project will be to conduct market research involving a competitive assessment of the current treatment on the market, along with a thorough technology review, customer validation, and eventually devising a go-to-market strategy for this new drug.